Parametric Response Mapping of Contrast-enhanced Biphasic CT for Evaluating Tumour Viability of Hepatocellular Carcinoma After TACE

Overview

Journal Eur Radiol

Specialty Radiology

Date 2016 Jan 16

PMID 26769666

Citations 7

Authors

Jan B Hinrichs

Hoen-Oh Shin

Daniel Kaercher

Davut Hasdemir

Tim Murray

Till Kaireit

Carolin Lutat

Arndt Vogel

Bernhard C Meyer

Frank K Wacker

Thomas Rodt

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the feasibility and role of parametric response mapping (PRM) for quantitative assessment of regional contrast-enhancement patterns in hepatocellular carcinoma (HCC).

Methods: Biphasic CT of 19 patients receiving repetitive conventional transarterial chemoembolisation (cTACE) for intermediate stage HCC were retrospectively analysed at baseline and follow-up at 3, 6, and 9 months. Voxel-based registration of arterial and porto-venous phases, with segmentation of the largest target lesion was performed. Frequency distribution plots of density-pairs of segmented voxels were generated. To differentiate necrotic, hypervascular and non-hypervascular tumour, and lipiodol/calcification, thresholds of 30, 100, and 300 HU were applied. Changes in density frequency plots over time were analysed and compared to response and assessment criteria (WHO, RECIST, EASL, mRECIST) and survival.

Results: PRM was feasible in all cases. Tumour volumes and hypervascular/non-hypervascular volume ratio showed significant longitudinal decrease (p < 0.05). Hypervascular volume at baseline was inversely correlated to survival (R = -0.57, p = 0.005). The only predictive parameter following cTACE to show significant survival difference was the change of the viable/non-viable ratio (p = 0.044), whereas common response assessment criteria showed no significant difference in survival.

Conclusions: PRM allows a quantitative and more precise assessment of regional tumour vascularisation patterns and may be helpful for TACE treatment planning and response assessment.

Key Points: • PRM allows more precise assessment of tumour vascularisation compared to conventional evaluation • PRM is beneficial for cTACE treatment planning and response assessment • PRM allows a quantitative assessment of regional contrast enhancement patterns.

Citing Articles

Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.

Deng K, Chen T, Leng Z, Yang F, Lu T, Cao J Radiol Med. 2024; 129(8):1099-1117.

PMID: 39060885 PMC: 11322429. DOI: 10.1007/s11547-024-01840-9.

Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization.

Mendiratta-Lala M, Aslam A, Bai H, Chapiro J, De Baere T, Miyayama S Eur Radiol. 2023; 34(5):3284-3297.

PMID: 37930412 PMC: 11126446. DOI: 10.1007/s00330-023-10326-7.

Efficacy Evaluation on the Color Doppler Ultrasound, Multislice Spiral CT Combined with Serum Markers in Diagnosis of Primary Hepatic Carcinoma.

Zhao X, Xia Y, Li C, Wang D Iran J Public Health. 2021; 50(8):1603-1612.

PMID: 34917531 PMC: 8643511. DOI: 10.18502/ijph.v50i8.6806.

Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy.

Meine T, Brunkhorst T, Werncke T, Schutze C, Vogel A, Kirstein M J Clin Med. 2021; 10(17).

PMID: 34501284 PMC: 8432038. DOI: 10.3390/jcm10173837.

[Locoregional and local ablative treatment options for liver tumors].

Hinrichs J, Wacker F Internist (Berl). 2020; 61(2):158-163.

PMID: 31919532 DOI: 10.1007/s00108-019-00725-8.

References

Federico A, Orditura M, Cotticelli G, de Sio I, Romano M, Gravina A . Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015; 9(4):1628-1632. PMC: 4356395. DOI: 10.3892/ol.2015.2960. View

Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S . Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2015; 26(6):1640-8. DOI: 10.1007/s00330-015-3982-y. View

Niessen C, Wiggermann P, Velandia C, Stroszczynski C, Pereira P . Transarterial chemoembolization - status quo in Germany. Rofo. 2013; 185(11):1089-94. DOI: 10.1055/s-0033-1335529. View

Park Y, Kim Y, Rhim H, Lim H, Choi D, Lee W . Arterial enhancement of hepatocellular carcinoma before radiofrequency ablation as a predictor of postablation local tumor progression. AJR Am J Roentgenol. 2009; 193(3):757-63. DOI: 10.2214/AJR.08.2202. View

Shah S, Cleary S, Wei A, Yang I, Taylor B, Hemming A . Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007; 141(3):330-9. DOI: 10.1016/j.surg.2006.06.028. View

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

Schima W, Ba-Ssalamah A, Kurtaran A, Schindl M, Gruenberger T . Post-treatment imaging of liver tumours. Cancer Imaging. 2007; 7 Spec No A:S28-36. PMC: 2727978. DOI: 10.1102/1470-7330.2007.9047. View

Choi J, Lee J, Sirlin C . CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014; 273(1):30-50. PMC: 4263770. DOI: 10.1148/radiol.14132362. View

Bruix J, Raoul J, Sherman M, Mazzaferro V, Bolondi L, Craxi A . Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57(4):821-9. DOI: 10.1016/j.jhep.2012.06.014. View

10.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

11.

Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs A . EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55(6):1309-16. DOI: 10.1016/j.jhep.2011.03.007. View

12.

Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z . Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015; 25(7):1993-2003. PMC: 4458393. DOI: 10.1007/s00330-015-3595-5. View

13.

Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E . Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011; 53(5):1580-9. DOI: 10.1002/hep.24246. View

14.

Shim J, Lee H, Kim S, Shin Y, Kim K, Lim Y . Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2011; 262(2):708-18. DOI: 10.1148/radiol.11110282. View

15.

Boas F, Kamaya A, Do B, Desser T, Beaulieu C, Vasanawala S . Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans. J Digit Imaging. 2014; 28(2):213-23. PMC: 4359206. DOI: 10.1007/s10278-014-9725-9. View

16.

Knox J, Cleary S, Dawson L . Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol. 2015; 33(16):1835-44. DOI: 10.1200/JCO.2014.60.1153. View

17.

Avants B, Epstein C, Grossman M, Gee J . Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2007; 12(1):26-41. PMC: 2276735. DOI: 10.1016/j.media.2007.06.004. View

18.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

19.

Choi S, Kim J, Seo J, Kim H, Lee J, Park H . Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol. 2015; 26(1):225-34. DOI: 10.1007/s00330-015-3825-x. View

20.

Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton M . MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2009; 33(3):532-40. DOI: 10.1007/s00270-009-9728-y. View